Spectrum Pharmaceuticals Announces FDA's Acceptance Of Ozarelix IND And Approval Of Phase 2b Protocol In BPH (Benign Prostate Hypertrophy)

... Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for ozarelix in Benign Prostate Hypertrophy (BPH) and that the FDA has approved the protocol for the Phase 2b study of ozarelix for the treatment of BPH. Dr. [click link for full article] ...